GOP Warning Over US Health Care Legislation

23 June 1996

The US Congress must reach agreement with the Clinton Administration on a health care bill before it goes into recess for the Fourth of July or the bill will probably die, says new Senate majority leader Trent Lott.

The Republicans and the White House have been trading offers, and Sen Lott and Senate Democrat leader Tom Daschle are guardedly optimistic that they are close to a bill allowing health insurance portability for workers changing jobs. The key dispute is over GOP plans for medical savings accounts, which Sen Lott called "one of the most hopeful innovations since antibiotics," and urged President Clinton to withdraw his threat of a veto for the reform. He hoped Pres Clinton would "use his influence to win over his own party to overcome the threat of filibuster against this vital legislation." Some Senators, including Edward Kennedy, are willing to block the entire reform package rather than allow the accounts, he said.

Pres Clinton is willing to accept an experimental project on the accounts, said White House aide George Stephanopoulos; the insurance reform bill passed the Senate unanimously without this provision. Republicans should not end any chance for reform by insisting on unconstrained, massive use of the accounts, he added. The GOP has already agreed a compromise allowing the self-employed and firms with under 50 workers to try the accounts from January. If successful, after three years, they would be open to larger firms, unless Congress says no.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight